Reason reports back from Rejuvenation Startup Summit 2024
Fight Aging! - 13-May-2024A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
SENISCA
University of Exeter spinout developing senotherapeutic interventions through modulation of dysregulated RNA splicing
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics).
Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells.
At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing. SENISCA interventions are small molecule or oligonucleotide-based.
Senisca Executive Team
- Sarah Cole, CEO
- Lorna Harries - CSO
- Ben Lee - CTO
- Kirsty Semple - COO
- Tim Schmidt - CDO
Senisca Advisory Board
- David Chiswell - Chairman
- Allan Weiner - Non-Executive Director
- Scott Beattie - Non-Executive Director
- Richard Haycock - Non-Executive Director
- Steve Wilton - Scientific Advisor
Visit website: https://www.senisca.com/
See also: 
University of Exeter
- UK university and member of the Russell Group of leading research-intensive UK universities
Details last updated 05-Aug-2020
Mentioned in this Resource
SENISCA News
SENISCA secures 3.7 million euros to fight aging with RNA-based therapies
Longevity Technology - 18-Mar-2024Developing senotherapeutics to target cellular senescence and treat age-related diseases
UK biotech races US giants for longevity breakthrough
The Guardian - 05-Nov-2023British researchers and startups vie to outpace tech billionaires in the fight against ageing
Reason reports back from Age-Related Disease Therapeutics Summit 2023
Fight Aging! - 16-Jun-2023Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years
Exeter's company SENISCA raises £2 million to treat age-related chronic diseases
University of Exeter - 09-Jun-2022Funding might allow RNA-based rejuvenation tech to enter ex vivo lab tests
SENISCA to reverse senescence by targeting RNA splicing patterns
Longevity Technology - 08-Apr-2022Lorna Harries details significant breakthroughs at fourth annual Longevity Leaders World Congress
SENISCA targets sensescence using a new ageing hallmark - dysregulated mRNA processing
Lifespan.io (LEAF) - 03-Nov-2021Lorna Harries believes dysregulated splicing as a breakthrough senotherapeutic target
SENISCA secures 1.3 million pounds to transform anti-ageing technology
University of Exeter - 12-Mar-2021Spin out company from University of Exeter step forward towards precision medicine for age-related diseases
LMC provides background and success outlook on 14 leading senolytic companies
Longevity Marketcap - 15-Dec-2020Comprehensive review of companies' clinical and financial state of play
Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
Taking the new path in the field of senolytics - SENISCA
Longevity Technology - 29-Jul-2020Old cells will be more young and beautiful
Topics mentioned on this page:
Senescent Cells
